ArticleMolecular cancer2014
MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance.
Article in Molecular cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 168 citations in OpenAlex.
- MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data.British journal of cancer · 2022Pooled it
- MicroRNAs in Prostate Cancer Liquid Biopsies: Early Detection, Prognosis, and Treatment Monitoring.Cells · 2026Review
- Machine Learning Approach Identifies miRNA Biomarkers for Post Surgical Patient Stratification in Prostate Cancer.The Prostate · 2025Article
- Mapping genetic variability in mature miRNAs and miRNA binding sites in prostate cancer.Journal of human genetics · 2021Article
- miR-145-5p: A Potential Biomarker in Predicting Gleason Upgrading of Prostate Biopsy Samples Scored 3+3=6.Cancer management and research · 2021Article
- MicroRNAs as Guardians of the Prostate: Those Who Stand before Cancer. What Do We Really Know about the Role of microRNAs in Prostate Biology?International journal of molecular sciences · 2020Review
- Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-β signaling.Theranostics · 2019Article
- Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer.BMC cancer · 2018Article
- Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles.Scientific reports · 2017Article
- MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1.Oncology letters · 2017Article
- The roles of microRNAs in the progression of castration-resistant prostate cancer.Journal of human genetics · 2017Review
- Computational Analysis of Specific MicroRNA Biomarkers for Noninvasive Early Cancer Detection.BioMed research international · 2017Article
- MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.Disease markers · 2017Article
- c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.Oncotarget · 2016Article
- The other face of miR-17-92a cluster, exhibiting tumor suppressor effects in prostate cancer.Oncotarget · 2016Article
- MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth.Molecular oncology · 2015Article
- miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.Molecular endocrinology (Baltimore, Md.) · 2015Article
- Translationally controlled tumor protein in prostatic adenocarcinoma: correlation with tumor grading and treatment-related changes.BioMed research international · 2015Article
- MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1.Molecular cancer · 2014Article
- MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samples.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDevelopment of resistance to androgen deprivation therapy (ADT) is a major obstacle for the management of advanced prostate cancer. Therapies with androgen receptor (AR) antagonists and androgen withdrawal initially regress tumors but development of compensatory mechanisms including AR bypass signaling leads to re-growth of tumors. MicroRNAs (miRNAs) are small regulatory RNAs that are involved in maintenance of cell homeostasis but are often altered in tumor cells.
resultsIn this study, we determined the association of genome wide miRNA expression (1113 unique miRNAs) with development of resistance to ADT. We used androgen sensitive prostate cancer cells that progressed to ADT and AR antagonist Casodex (CDX) resistance upon androgen withdrawal and treatment with CDX. Validation of expression of a subset of 100 miRNAs led to identification of 43 miRNAs that are significantly altered during progression of cells to treatment resistance. We also show a correlation of altered expression of 10 proteins targeted by some of these miRNAs in these cells.
conclusionsWe conclude that dynamic alterations in miRNA expression occur early on during androgen deprivation therapy, and androgen receptor blockade. The cumulative effect of these altered miRNA expression profiles is the temporal modulation of multiple signaling pathways promoting survival and acquisition of resistance. These early events are driving the transition to castration resistance and cannot be studied in already developed CRPC cell lines or tissues. Furthermore our results can be used a prognostic marker of cancers with a potential to be resistant to ADT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.